News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
May, 2025
May 2025
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Praveen Kumar Marimuthu: Pembrolizumab in previously treated patients with Advanced Clear Cell Gynecological Cancer
Praveen Kumar Marimuthu/X
May 1, 2025, 09:14

Praveen Kumar Marimuthu: Pembrolizumab in previously treated patients with Advanced Clear Cell Gynecological Cancer

Praveen Kumar Marimuthu, DM Resident in Medical Oncology at Christian Medical College and Hospital, shared an article by Rebecca Kristeleit, et al. on X:

“Pembrolizumab in previously treated patients with Advanced Clear Cell Gynecological Cancer.

  • 12-wk PFS: 42%.
  • ORR: 25%.
  • Median DOR: 13.1 mo.
  • Median OS: 14.8 mo.”

Praveen Kumar Marimuthu: Pembrolizumab in previously treated patients with Advanced Clear Cell Gynecological Cancer

Pembrolizumab in Patients With Advanced Clear Cell Gynecological Cancer: A Phase 2 Nonrandomized Clinical Trial.

Journal: Jama Network

Authors: Rebecca Kristeleit, Michael-John Devlin, Andrew Clamp, Charlie Gourley, René Roux, Marcia Hall, Rachel Nirsimloo, Valentinos Kounnis, Lesley Sage, Priya Narayanan, C. Simon Herrington, Rupali Arora, Laura Farrelly, Laura Hughes, Nicholas Counsel, Rowan E. Miller, et al.

You can Read the Full Article on Journal of JAMA NETWORK.

Praveen Kumar Marimuthu: Pembrolizumab in previously treated patients with Advanced Clear Cell Gynecological Cancer

More posts featuring Praveen Kumar Marimuthu.

Advanced Clear Cell Gynecological Cancer Andrew Clamp C. Simon Herrington cancer Charlie Gourley Christian Medical College and Hospital clinical trial fight against cancer Global fight against cancer Gynecological Cancer JAMA Network Laura Farrelly Laura Hughes Lesley Sage Marcia Hall MedOnc Michael-John Devlin Nicholas Counsel OncoDaily Oncology pembrolizumab Praveen Kumar Marimuthu Priya Narayanan Rachel Nirsimloo Rebecca Kristeleit René Roux Rowan E. Miller Rupali Arora Valentinos Kounnis
Special Coverage
Blog
May 1, 2025, 14:51
Project grants in HPV vaccination - UICC
Insight
May 1, 2025, 14:32
Oscar Tahuahua Shares NEJM Study on Nonoperative PD-1 Blockade in dMMR Tumors
Blog
May 1, 2025, 14:30
Anirban Maitra Reflects on AACR 2025 and Thanks the Organizers
Blog
May 1, 2025, 14:00
ASH Highlights Role of Mass Spectrometry in Diagnosing MGTS
Blog
May 1, 2025, 13:26
Julie Torode Announces CEO Opportunity at World Ovarian Cancer Coalition
Blog
May 1, 2025, 13:23
Ally Mwambela: To Ensure Seamless Collaboration or Communication with Erick Mahatara, Kindly Reach Out to Him Directly Via Email
Blog
May 1, 2025, 13:03
Meet ESTRO 2025 Social Media Ambassadors
Blog
May 1, 2025, 12:47
Population-based Helicobacter Pylori Screen-and-treat Strategies for Gastric Cancer Prevention - IARC
Blog
May 1, 2025, 12:45
Rabi Hanna: So grateful to be invited to POEM Group 4th Scientific Conference
Blog
May 1, 2025, 12:23
Katie Coleman Reunites with Surgeon Jonathan Hernandez at AACR25 After Stage IV Cancer Journey - NCI CCR
Blog
May 1, 2025, 12:22
Fight Colorectal Cancer: Colon cancer is on the rise—but so is progress
Blog
May 1, 2025, 12:16
Catherine Alix-Panabières: AACR2025 is coming to an end — a fantastic opportunity to reconnect and learn